07.10.2025 • Topics

20 Years of CHEManager International

Incredible but true: CHEManager International is celebrating its 20th anniversary!

To mark this major milestone, we’re publishing a special edition:
“20 Years of CHEManager International” — coming December 10.

Join the celebration and position your brand among the industry’s elite by placing a congratulatory ad. But don’t wait too long — the deadline for submissions is November 14.

All print ad bookings include a complimentary banner ad in the CHEManager International newsletter as a value-added benefit.

CHEManager International is the premier media brand for the chemical, pharmaceutical, and biotech industries, reaching over 120,000 executives worldwide.  

This anniversary edition offers a unique opportunity to align your message with a trusted publication that has shaped the industry for two decades. Celebrate with us and make your brand part of this historic moment.

Put your brand in the spotlight in CHEManager International’s 20th anniversary issue!

Secure your spot

👉 Book your ad now to reach top industry decision-makers!

Book Now!
20 Years of CHEManager International
© Wiley
Thorsten Kritzer

Contact

Thorsten Kritzer

Head of Advertising

Tel.: +49 (0) 6201 606 730

tkritzer@wiley.com

Company

Logo:

CHEManager International c/o Wiley-VCH GmbH

Boschstrasse 12
69469 Weinheim
Germany

Company contact







Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read